drugset
Drugs / Aztreonam lysine
last change Mar 2025 re-read 3 minutes ago

Aztreonam lysine

also known as Cayston
Developed for
bronchiectasis

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Cayston — 2009-09-21 europa.eu ↗

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 4 NCT03696290 Comparator Oct 2019 → Nov 2024 bronchiectasis University of Dundee Terminated No outcome recorded Stop: Enrollment

Press releases naming this drug 3 releases

DateIssuerRelease
2010-10-21 Gilead Sciences Gilead's Cayston(R) Superior to Tobramycin Inhalation Solution in Six-Month Head-to-Head Cystic Fibrosis Study gilead.com ↗
2010-06-18 Gilead Sciences Gilead's Head-to-Head Study of Cayston(R) Versus Tobramycin Inhalation Solution in Cystic Fibrosis Patients Achieves Co-Primary Efficacy Endpoint of Non-Inferiority gilead.com ↗
2009-09-23 Gilead Sciences European Commission Grants Conditional Marketing Authorization to Cayston(R) (Aztreonam Lysine) for the Treatment of Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis gilead.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Aztreonam lysine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03696290 ↗
Known as Cayston “A Trial of the Safety, Tolerability and Efficacy of 2 Doses of Cayston (Aztreonam Lysine) Compared to Placebo in Participants With Bronchiectasis” NCT03696290 ↗
Route Inhaled “Nebulised aztreonam lysine 75mg” NCT03696290 ↗